Five-year relative survival for localised breast cancer is 100.0%. Across all stages it is 91.9%. Those are among the best figures in oncology, and underwriting reflects them — breast cancer is one of the more insurable cancer histories, provided the file is presented properly.
Our cancer history page covers the category generally. This page deals with breast specifically: what the postpone clock is actually measuring, and the one thing applicants most often get wrong about their own file.
The numbers underwriters are working from
SEER’s figures for 2016–2022 give five-year relative survival by stage as 100.0% localised, 87.5% regional, and 33.8% distant. (SEER)
The practical consequence is that early-stage breast cancer, sufficiently far from treatment, frequently reaches standard or near-standard rates — an outcome that is uncommon across cancer histories generally and surprises people who have been told a diagnosis makes them uninsurable.
The stage separation is real but far less extreme than in lung cancer, which is why breast files have more room in the middle. Regional disease at 87.5% is still a file a carrier can price with a rating rather than a decline.
What is on the pathology report, and why it matters
Stage alone does not describe a breast cancer file. Carriers look at the pathology in more detail here than in most cancers, because the detail genuinely predicts:
- Tumour size and node status — the two components doing most of the work in the stage itself
- Grade — how aggressive the cells look, independent of how far they had spread
- Hormone receptor status — ER and PR positive or negative
- HER2 status
- Triple-negative — ER, PR and HER2 all negative, which is assessed more cautiously and typically carries a longer postpone
- DCIS — ductal carcinoma in situ, non-invasive, and underwritten far more favourably than invasive disease. If yours was DCIS, make certain the application records it as such rather than as breast cancer generically. This is the single most common avoidable mis-rating in the category.
Supply the pathology report itself. An underwriter reading the actual document does not have to assume the least favourable reading of an ambiguous application answer.
Hormone therapy helps your file, not the reverse
This is the thing applicants most often misread about themselves.
Adjuvant endocrine therapy — tamoxifen, anastrozole, letrozole, exemestane — is typically prescribed for five to ten years after treatment for hormone-receptor-positive disease. A great many people assume that still being on medication means they are still a cancer patient, and either delay applying until they finish or apologise for it on the form.
Underwriters read it the other way. Ongoing endocrine therapy is evidence of adherence to a recurrence-reduction protocol. It tells the carrier that the disease was hormone-receptor-positive, which is the more favourable biology, and that you are doing the thing that lowers recurrence risk. Stopping early, or a pharmacy record showing gaps in refills, is the version that reads badly.
Do not delay an application in order to finish endocrine therapy first. It is a common instinct and it costs you years of cover for no underwriting benefit.
What the clock is measuring
Carriers apply a postpone period after treatment ends, and then price the file against how long you have been clear. Recurrence risk in breast cancer is front-loaded but has a long tail, particularly in hormone-receptor-positive disease, and the underwriting mirrors that shape: sharp improvement in the first few years, continued gradual improvement afterwards.
Practitioners report postpone periods measured in a small number of years for early-stage disease and longer for node-positive or triple-negative disease, with the better classes reserved for applicants well clear of treatment. Those are conventions rather than published thresholds — carrier manuals are not public, as our how underwriting works page explains.
Two dates matter and they are not the same date. The date active treatment ended — surgery, chemotherapy, radiation — is what starts the clock. Ongoing endocrine therapy does not stop that clock from running. Applicants routinely give the wrong date and land in a worse band than their history warrants.
A rating is often temporary
Two mechanisms are worth knowing about, because neither is applied automatically.
Some carriers price post-cancer files with a flat extra — a fixed additional cost per thousand of cover that expires after a set number of years — rather than a permanent table rating. Ask which structure an offer uses. A flat extra that falls away in five years is a materially better offer than a permanent rating at a similar first-year premium.
And a rating already in force can be revisited. Most carriers accept a reconsideration request once you are further from treatment, re-reviewing the file against current guidance. Nobody does this for you and there is no annual review. If you were rated three years ago and have been clear since, that is worth a phone call to whoever wrote the policy.
What to have ready
- The pathology report — stage, grade, size, node status, receptor and HER2 status
- Treatment summary with dates, and specifically the date active treatment ended
- Current endocrine therapy, dose and start date
- Most recent surveillance imaging and the interval you are on
- A recent oncology note confirming no evidence of disease
- Any genetic testing result. BRCA status is assessed, and a positive result with a completed risk-reducing mastectomy is a different file from a positive result without one
What to do next
Find the date your active treatment ended and check your pathology report for whether the diagnosis was invasive or in situ. Those two facts place you on the map more precisely than any general guidance can.
If you are inside the postpone window, guaranteed issue will bridge it, and holding it does not prevent a proper application later. If you are past it, apply with the pathology report attached and ask each carrier whether the offer is a flat extra or a table rating — that question alone can be worth more than shopping on headline premium.